Batiraxcept

Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis[1][2][3].

Product Specifications

CAS Number

[2268717-61-7]

Product Name Alternative

AVB-500; AVB-S6-500

UNSPSC

12352203

Target

Akt; p38 MAPK; PI3K; TAM Receptor

Type

Inhibitory Antibodies

Related Pathways

MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/batiraxcept.html

Purity

99.91

Solubility

10 mM in DMSO

Smiles

[Batiraxcept]

Molecular Weight

(93.85 kDa)

References & Citations

[3]Toboni MD, et al. Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer. Cancers (Basel) . 2021 Nov 23;13 (23) :5877.|[1]Bruce SF, et al. GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. Mol Cancer Ther. 2022 Aug 2;21 (8) :1348-1359.|[2]Kim J, et al. Targeting AXL Using the AVB-500 Soluble Receptor and through Genetic Knockdown Inhibits Bile Duct Cancer Growth and Metastasis. Cancers (Basel) . 2023 Mar 21;15 (6) :1882.